Carfilzomib can lead to cardiovascular toxicity in multiple myeloma patients

The proteasome inhibitor carfilzomib has taken on an increasing role in the treatment of multiple myeloma, but new research shows the therapy comes with the risk of cardiovascular problems in a higher than expected percentage of patients.